Recently, Borui Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as the "Company") has received the Certificate of Suitability (CEP) to the European Pharmacopoeia (hereinafter referred to as "CEP") issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM") for its nicergoline active pharmaceutical ingredient (API). We hereby announce the relevant information as follows:
I. Basic Information of the Drug
Name of chemical API: Nicergoline/NICERGOLINEManufacturer/Holder of the drug: Borui Biopharmaceutical (Suzhou) Co., Ltd.Certificate No.: CEP 2023-311-Rev 00Issuing authority: European Directorate for the Quality of Medicines & HealthCare (EDQM)Validity period: Valid for five years starting from February 1, 2024
II. Other Relevant Information of the Drug
Nicergoline is indicated for the treatment of senile dementia, vascular migraine, transient cerebral ischemia, excessive platelet aggregation and macular degeneration. The Company submitted the CEP application for its nicergoline API to EDQM in August 2023 and obtained the CEP certificate on February 1, 2024.












